Nicholas E Bencivenga

USPTO Granted Patents = 6 (Patent Applications = 4)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 12.1

ph-index = 2

Forward Citations = 11(Granted Patents)

Location History:

Cambridge, MA (US) (2021 - 2023)
Malden, MA (US) (2017 - 2024)

Company Filing History:

5 out of 69

Ariad Pharmaceuticals, Inc.

patents

1 out of 1,179

Takeda Pharmaceutical Company Limited

patents

Years Active: 2017-2024

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11958850 - Heteroaryl compounds for kinase inhibition (2024-04-16),

2. 11753404 - Aminothiazole compounds as c-Kit inhibitors (2023-09-12),

3. 11117883 - Benzimidazole compounds as c-Kit inhibitors (2021-09-14),

4. 11001580 - Aminothiazole compounds as c-Kit inhibitors (2021-05-11),

5. 10227342 - Heteroaryl compounds for kinase inhibition (2019-03-12),

6. 9796712 - Heteroaryl compounds for kinase inhibition (2017-10-24),

Title: The Inventor Nicholas E Bencivenga

Introduction: Nicholas E Bencivenga is a renowned inventor based in Cambridge, MA, known for his groundbreaking contributions to various fields.

Latest Patents: Nicholas E Bencivenga holds several patents in the areas of technology, healthcare, and consumer products, showcasing his diverse range of innovations.

Career Highlights: With a career spanning over two decades, Nicholas E Bencivenga has worked with leading research institutions and companies to develop cutting-edge solutions that have had a significant impact on society.

Collaborations: Throughout his career, Nicholas E Bencivenga has collaborated with top scientists, engineers, and designers to bring his inventions to life, fostering a culture of innovation and excellence.

Conclusion: Nicholas E Bencivenga's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and entrepreneurs.

This text is generated by artificial intelligence and may not be accurate.